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Prescribing statins for patients 
with ACS? No need to wait
The best time to start a statin in patients with acute 
coronary syndrome is before they undergo percutaneous 
coronary intervention.
PRACTICE CHANGER
Prescribe a high-dose statin before any pa-
tient with acute coronary syndrome (ACS) 
undergoes percutaneous coronary interven-
tion (PCI); it may be reasonable to extend this 
to patients being evaluated for ACS.1
StRENGtH oF RECoMMENDAtioN
A: Based on a meta-analysis
Navarese EP, Kowalewski M, Andreotti F, et al. Meta-analysis of time-
related benefits of statin therapy in patients with acute coronary syn-
drome undergoing percutaneous coronary intervention. Am J Cardiol. 
2014;113:1753-1764.
ILLUSTRATIVE CASE
A 48-year-old man comes to the emergency 
department with chest pain and is diagnosed 
with ACS. He is scheduled to have PCI within 
the next 24 hours. When should you start him 
on a statin? 
Statins are the mainstay pharmaceuti-cal treatment for hyperlipidemia, and are used for primary and secondary 
prevention of coronary artery disease and 
stroke.2,3 Well-known for their cholesterol-
lowering effect, they also have benefits that 
are independent of their effects on lipids, 
including improving endothelial function, 
decreasing oxidative stress, and decreasing 
vascular inflammation.4-6
Compared to patients with stable an-
gina, patients with ACS experience markedly 
higher rates of coronary events, especially 
immediately before and after PCI and during 
the subsequent 30 days.1 American College 
of Cardiology/American Heart Association 
(ACC/AHA) guidelines for the management 
of non-ST elevation myocardial infarction 
(NSTEMI) advocate starting statins before 
patients are discharged from the hospital, but 
they don’t specify precisely when.7
Considering the higher risk of coronary 
events before and after PCI and statins’ pleio-
tropic effects, it is reasonable to investigate 
the optimal time for starting statins in pa-
tients with ACS. 
STUDY SUMMARY
Meta-analysis of 20 RCts shows  
statins before PCi cuts risk of Mi
Navarese et al1 performed a systematic re-
view and meta-analysis of studies compar-
ing the clinical outcomes of patients with 
ACS who received statins before or after PCI 
(statins group) vs those who received low-
dose statins or no statins (control group). 
The authors searched PubMed, Cochrane, 
Google Scholar, and CINAHL databases as 
well as key conference proceedings for stud-
ies published before November 2013. Using 
reasonable inclusion and exclusion criteria 
and appropriate statistical methods, they 
analyzed the results of 20 randomized con-
trolled trials that included 8750 patients. 
Four studies enrolled only patients with ST 
elevation MI, 8 were restricted to NSTEMI, 
and the remaining 8 studies enrolled patients 
with any type of MI or unstable angina.
When would you  
typically start  
a statin for  
patients with 
acute coronary  
syndrome (ACS)? 
n  As soon as they 
present with 
symptoms that 
suggest ACS
n  A few days to a 
few hours before 
they undergo 
percutaneous 
coronary  
intervention (PCI)
n  A few hours to 
a few days after 
they undergo PCI
n  I would not 
prescribe a statin 
for these patients
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For patients who were started on a statin 
before PCI, the mean timing of administra-
tion was 0.53 ± 0.42 days before. For those 
started after PCI, the average time to admin-
istration was 3.18 ± 3.56 days after. 
Whether administered before or after 
PCI, statins reduced the incidence of MIs. 
The overall 30-day incidence of MIs was 3.4% 
(123 of 3621) in the statins group and 5% 
(179 of 3577) in the control group. This re-
sulted in an absolute risk reduction of 1.6% 
(number needed to treat=62.5), and a re-
duction of the odds of MI by 33% (odds ra-
tio [OR]=0.67; 95% confidence interval [CI], 
0.53-0.84; P=.0007). There was also a trend 
toward reduced mortality in the statin group 
(OR=0.66; 95% CI, 0.43-1.02; P=.06).
In addition, administering statins be-
fore PCI resulted in a greater reduction in 
the odds of MI at 30 days (OR=0.38; 95% CI, 
0.24-0.59; P<.0001) than starting them post-
PCI (OR=0.85; 95% CI, 0.64-1.13; P=.28) when 
compared to the controls. The difference be-
tween the pre-PCI OR and the post-PCI OR 
was statistically significant (P=.002). These 
findings persisted past 30 days (P=.06).
WHAT’S NEW
Early statin administration  
is most effective
According to ACC/AHA guidelines, all pa-
tients with ACS should be receiving a statin 
by the time they are discharged. However, 
when to start the statin is not specified. This 
meta-analysis is the first report to show that 
administering a statin before PCI can signifi-
cantly reduce the risk of subsequent MI.
CAVEATS
Benefits might vary 
with different statins
The studies evaluated in this meta-analysis 
used various statins and dosing regimens, 
which could have affected the results. Howev-
er, sensitivity analyses found similar benefits 
across different types of statins. In addition, 
most of the included trials used high doses 
of statins, which minimized the potential 
discrepancy in outcomes from various dos-
ing regimens. And while the included studies 
were not perfect, Navarese et al1 used reason-
able methods to identify potential biases.  
CHALLENGES TO IMPLEMENTATION
No barriers  
to starting statins earlier
Implementing this intervention may be as 
simple as editing a standard order. This meta-
analysis also suggests that the earlier the in-
tervention, the greater the benefit, which may 
be an argument for starting a statin when a 
patient first presents for evaluation for ACS, 
since the risks of taking a statin are quite low. 
We believe it would be beneficial if the next 
update of the ACC/AHA guidelines7 included 
this recommendation.                 JFP
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Administering 
statins before 
PCi resulted  
in a greater 
reduction in the 
odds of Mi than 
starting them 
afterward. 
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